These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

296 related items for PubMed ID: 12910434

  • 1. Glatiramer acetate treatment in patients with childhood and juvenile onset multiple sclerosis.
    Kornek B, Bernert G, Balassy C, Geldner J, Prayer D, Feucht M.
    Neuropediatrics; 2003 Jun; 34(3):120-6. PubMed ID: 12910434
    [Abstract] [Full Text] [Related]

  • 2. Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
    Metz LM, Li D, Traboulsee A, Myles ML, Duquette P, Godin J, Constantin M, Yong VW, GA/minocycline study investigators.
    Mult Scler; 2009 Oct; 15(10):1183-94. PubMed ID: 19776092
    [Abstract] [Full Text] [Related]

  • 3. Immunomodulatory treatment of early onset multiple sclerosis: results of an Italian Co-operative Study.
    Ghezzi A, Immunomodulatory Treatment of Early Onset MS (ITEMS) Group.
    Neurol Sci; 2005 Dec; 26 Suppl 4():S183-6. PubMed ID: 16388355
    [Abstract] [Full Text] [Related]

  • 4. European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
    Comi G, Filippi M, Wolinsky JS.
    Ann Neurol; 2001 Mar; 49(3):290-7. PubMed ID: 11261502
    [Abstract] [Full Text] [Related]

  • 5. Long-term follow up of glatiramer acetate compassionate use in Belgium.
    Sindic CJ, Seeldrayers P, Vande Gaer L, De Smet E, Nagels G, De Deyn PP, Medaer R, Guillaume D, D'Hooghe MB, Deville MC, Decoo D, Sadzot B, Van Landegem W, Strauven T, Pepin J, Merckx H, Caekebeke J, van der Tool MA.
    Acta Neurol Belg; 2005 Jun; 105(2):81-5. PubMed ID: 16076061
    [Abstract] [Full Text] [Related]

  • 6. [Long-term effects of glatiramer acetate in multiple sclerosis].
    Brochet B.
    Rev Neurol (Paris); 2008 Nov; 164(11):917-26. PubMed ID: 18790510
    [Abstract] [Full Text] [Related]

  • 7. Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing-remitting MS.
    Cohen JA, Rovaris M, Goodman AD, Ladkani D, Wynn D, Filippi M, 9006 Study Group.
    Neurology; 2007 Mar 20; 68(12):939-44. PubMed ID: 17372130
    [Abstract] [Full Text] [Related]

  • 8. Benefits of glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis.
    Johnson KP, Due DL.
    Expert Rev Pharmacoecon Outcomes Res; 2009 Jun 20; 9(3):205-14. PubMed ID: 19527092
    [Abstract] [Full Text] [Related]

  • 9. Short-term combination of glatiramer acetate with i.v. steroid treatment preceding treatment with GA alone assessed by MRI-disease activity in patients with relapsing-remitting multiple sclerosis.
    De Stefano N, Filippi M, Hawkins C, 9011 study group.
    J Neurol Sci; 2008 Mar 15; 266(1-2):44-50. PubMed ID: 17897678
    [Abstract] [Full Text] [Related]

  • 10. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, Lisak RP, Myers LW, Panitch HS, Pruitt A, Rose JW, Kachuck N, Wolinsky JS.
    Mult Scler; 2000 Aug 15; 6(4):255-66. PubMed ID: 10962546
    [Abstract] [Full Text] [Related]

  • 11. Patterns of TH1/TH2 cytokines predict clinical response in multiple sclerosis patients treated with glatiramer acetate.
    Tumani H, Kassubek J, Hijazi M, Lehmensiek V, Unrath A, Süssmuth S, Lauda F, Kapfer T, Fang L, Senel M, Brettschneider J.
    Eur Neurol; 2011 Aug 15; 65(3):164-9. PubMed ID: 21372576
    [Abstract] [Full Text] [Related]

  • 12. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ, Cowan BJ, Moore GR, Hashimoto SA.
    J Cutan Pathol; 2008 Apr 15; 35(4):407-10. PubMed ID: 18333902
    [Abstract] [Full Text] [Related]

  • 13. [Use of glatiramer acetate (Copaxone) in the treatment of patients with multiple sclerosis. Experience of the Moscow multiple sclerosis center].
    Demina TL, Davydovskaia MV, Lashch NIu, Popova NF, Khachanova NV, Zhuchenko TD.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003 Apr 15; (Spec No 2):91-7. PubMed ID: 12938642
    [Abstract] [Full Text] [Related]

  • 14. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, Kita M, Yang M, Raghupathi K, Novas M, Sweetser MT, Viglietta V, Dawson KT, CONFIRM Study Investigators.
    N Engl J Med; 2012 Sep 20; 367(12):1087-97. PubMed ID: 22992072
    [Abstract] [Full Text] [Related]

  • 15. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis.
    Miller A, Spada V, Beerkircher D, Kreitman RR.
    Mult Scler; 2008 May 20; 14(4):494-9. PubMed ID: 18208875
    [Abstract] [Full Text] [Related]

  • 16. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T, Bereczki D.
    Ideggyogy Sz; 2004 Nov 20; 57(11-12):401-16. PubMed ID: 15662768
    [Abstract] [Full Text] [Related]

  • 17. Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
    Vollmer T, Panitch H, Bar-Or A, Dunn J, Freedman MS, Gazda SK, Campagnolo D, Deutsch F, Arnold DL.
    Mult Scler; 2008 Jun 20; 14(5):663-70. PubMed ID: 18424479
    [Abstract] [Full Text] [Related]

  • 18. A reassessment of the plateauing relationship between T2 lesion load and disability in MS.
    Sormani MP, Rovaris M, Comi G, Filippi M.
    Neurology; 2009 Nov 10; 73(19):1538-42. PubMed ID: 19794123
    [Abstract] [Full Text] [Related]

  • 19. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
    Kappos L, Traboulsee A, Constantinescu C, Erälinna JP, Forrestal F, Jongen P, Pollard J, Sandberg-Wollheim M, Sindic C, Stubinski B, Uitdehaag B, Li D.
    Neurology; 2006 Sep 26; 67(6):944-53. PubMed ID: 17000959
    [Abstract] [Full Text] [Related]

  • 20. Neurologic consequence of delaying glatiramer acetate therapy for multiple sclerosis: 8-year data.
    Johnson KP, Ford CC, Lisak RP, Wolinsky JS.
    Acta Neurol Scand; 2005 Jan 26; 111(1):42-7. PubMed ID: 15595937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.